Article
A genetic variation in microRNA target site of ETS2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer.
Oncotarget - 29 Mar 2016
Hong Mi Jeong, Lee Shin Yup, Choi Jin Eun, Jin Cheng Cheng, Kang Hyo Jung, Baek Sun Ah, Lee So Yeon, Shin Kyung Min, Jeong Ji Yun, Lee Won Kee, Yoo Seung Soo, Lee Jaehee, Cha Seung Ick, Kim Chang Ho, Son Ji Woong, Park Jae Yong
Abstract excerpt
The present study was performed to investigate the association of single nucleotide polymorphisms (SNPs) located in the miRNA target sites with the clinical outcomes of first line paclitaxel-cisplatin chemotherapy in advanced NSCLC. Eighty SNPs in miRNA binding sites of cancer related genes selected from 18,500 miRNA:target bindings in crosslinking, ligation, and sequencing of hybrids (CLASH) data were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
